ストックスクリーナーアプリを入手
19.51
1.22%
-0.24
アフターアワーズ：
19.58
0.07
+0.36%
前日終値:
$19.75
開ける：
$19.87
24時間の取引高:
1.85M
Relative Volume:
0.40
時価総額：
$1.22B
収益：
$14.34M
当期純損益:
$-199.00M
株価収益率:
-4.977
EPS:
-3.92
ネットキャッシュフロー:
$-183.51M
1週間 パフォーマンス:
-8.53%
1か月 パフォーマンス:
-35.23%
6か月 パフォーマンス:
+22.01%
1年 パフォーマンス:
+29.55%
1日の値動き範囲:
$19.34
$20.00
1週間の範囲:
$19.34
$22.11
52週間の値動き範囲:
$7.76
$71.50
Uniqure N V Stock (QURE) Company Profile
QURE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
19.51 | 1.23B | 14.34M | -199.00M | -183.51M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-04 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2025-08-14 | アップグレード | Mizuho | Neutral → Outperform |
| 2025-04-01 | 再開されました | Chardan Capital Markets | Buy |
| 2024-12-10 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | 再開されました | Raymond James | Outperform |
| 2024-02-29 | ダウングレード | Goldman | Buy → Neutral |
| 2023-12-19 | ダウングレード | Mizuho | Buy → Neutral |
| 2022-03-17 | アップグレード | UBS | Neutral → Buy |
| 2021-06-15 | 開始されました | BTIG Research | Buy |
| 2021-05-21 | 開始されました | UBS | Neutral |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-04-01 | アップグレード | Mizuho | Neutral → Buy |
| 2021-01-07 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-11-24 | 開始されました | H.C. Wainwright | Buy |
| 2020-11-11 | 開始されました | Berenberg | Buy |
| 2020-11-09 | 開始されました | Jefferies | Buy |
| 2020-11-04 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-10-23 | 開始されました | RBC Capital Mkts | Outperform |
| 2020-08-25 | 開始されました | Raymond James | Strong Buy |
| 2020-07-31 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | ダウングレード | Mizuho | Buy → Neutral |
| 2020-06-25 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | 開始されました | Cowen | Outperform |
| 2019-12-03 | 開始されました | Goldman | Buy |
| 2019-11-05 | 開始されました | Credit Suisse | Outperform |
| 2019-10-11 | 開始されました | Stifel | Buy |
| 2019-09-25 | 開始されました | Bernstein | Outperform |
| 2019-09-12 | 開始されました | Mizuho | Buy |
| 2019-07-30 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-07-08 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2019-04-12 | 開始されました | Piper Jaffray | Overweight |
| 2019-03-29 | 開始されました | Robert W. Baird | Outperform |
すべてを表示
Uniqure N V (QURE) 最新ニュース
Stifel Maintains uniQure N.V. (QURE) Buy Recommendation - Nasdaq
Roku To Rally More Than 28%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
uniQure (QURE) Price Target Lowered by Stifel Analyst | QURE Sto - GuruFocus
QURE Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - cnhinews.com
Mizuho Maintains uniQure N.V. (QURE) Outperform Recommendation - Nasdaq
Mizuho Lowers Price Target for uniQure (QURE) to $33.00 | QURE S - GuruFocus
Mizuho Securities Maintains UniQure NV(QURE.US) With Buy Rating, Maintains Target Price $33 - 富途牛牛
Swiss National Bank Makes New Investment in uniQure N.V. $QURE - MarketBeat
uniQure NV (HAM:UQ1) Non Operating Income : €-3.54 Mil (TTM As of Sep. 2025) - GuruFocus
uniQure NV (HAM:UQ1) Asset Impairment Charge : €0.00 Mil (TTM As of Sep. 2025) - GuruFocus
uniQure NV (HAM:UQ1) Total Long-Term Liabilities : €476.27 Mil (As of Sep. 2025) - GuruFocus
Notice of Investigation of QURE: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - GlobeNewswire Inc.
Voss Capital LP Takes $1.74 Million Position in uniQure N.V. $QURE - MarketBeat
Pale Fire Capital SE Boosts Stake in uniQure N.V. $QURE - MarketBeat
Progress on AMT-130 Halts uniQure N.V.’s (QURE) Downtrend - Insider Monkey
uniQure (NASDAQ:QURE) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
7 Hidden Multibagger Stocks to Invest In - Insider Monkey
Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years – Company AnnouncementFT.com - Financial Times
Aug Wrap: Can uniQure NV stock surprise with earnings upside2025 Key Highlights & Smart Swing Trading Techniques - BỘ NỘI VỤ
uniQure (NASDAQ:QURE) Shares Down 5.1%Here's What Happened - MarketBeat
QURE Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - Your Wyoming Link
QURE Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors With Significant Losses to Contact the Firm - NewMediaWire
uniQure (NASDAQ:QURE) Receives "Buy" Rating from Chardan Capital - MarketBeat
uniQure (NASDAQ:QURE) Shares Gap DownHere's What Happened - MarketBeat
How uniQure N.V. (UQ1) stock benefits from digital adoptionTrade Ideas & Scalable Portfolio Growth Methods - Newser
How strong is uniQure N.V. stock revenue growthJuly 2025 Sentiment & Scalable Portfolio Growth Ideas - Newser
uniQure (QURE) Is Down 17.3% After FDA Questions AMT-130 Data Sufficiency For BLAHas The Bull Case Changed? - simplywall.st
Chardan Capital Maintains uniQure N.V. (QURE) Buy Recommendation - Nasdaq
QURE Investigation Alert: Kessler Topaz Meltzer & Check, LLP Enc - GuruFocus
uniQure (QURE) Stock: Navigates Regulatory Hurdles for AMT-130 as FDA Requests Further Engagement - parameter.io
uniQure (QURE) Analyst Ratings: Chardan Capital Maintains Buy Ra - GuruFocus
Why uniQure Stock Is Trading Lower After FDA Meeting Update - Sahm
uniQure N.V. (QURE): A Bear Case Theory - Finviz
UniQure stock falls after FDA's notes on pre-application of AMT-130 - MSN
uniQure (QURE) Shares Plunge 20% on FDA Feedback for AMT-130 - GuruFocus
uniQure says FDA announced Phase I/II AMT-130 data unlikely to support BLA - TipRanks
uniQure stock falls after FDA signals data unlikely to support AMT-130 approval - Investing.com Australia
uniQure stock falls after FDA's notes on pre application of AMT-130 - Seeking Alpha
uniQure (QURE) Reassesses Strategy After FDA Feedback on AMT-130 Application - GuruFocus
UniQure Seeks US FDA Follow-Up Meeting After Being Told Data Do Not Support BLA Submission - marketscreener.com
Why Is UniQure Stock Falling In Pre-market? - Nasdaq
uniQure Faces Setback in Gene Therapy Approval - TipRanks
uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease - The Manila Times
uniQure N.V. Provides Regulatory Update on AMT-130 for Huntington's Disease - TradingView
Uniqure N.V. Provides Regulatory Update on Amt-130 for Huntington's Disease - marketscreener.com
uniQure (NASDAQ: QURE) receives FDA minutes on AMT-130 BLA path for Huntington’s disease - Stock Titan
uniQure N.V. $QURE Stake Reduced by Schroder Investment Management Group - MarketBeat
uniQure N.V. $QURE Shares Acquired by JPMorgan Chase & Co. - MarketBeat
(QURE) Risk Channels and Responsive Allocation - news.stocktradersdaily.com
uniQure N.V. (UQ1) Stock Price Prediction for 2026, 2030-2040 - Traders Union
Smart Money Is Betting Big In QURE Options - Benzinga
Uniqure N V (QURE) 財務データ
収益
当期純利益
現金流量
EPS
1.08%
0.91%
大文字化:
|
ボリューム (24 時間):